Deferiprone clinical trials
Also written L1.
How each study uses Deferiprone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Deferiprone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Oct 2011 · FERRIPROX · NDA 021825 (FDA, Drugs@FDA)
- European Union
- 25 Aug 1999 · Ferriprox · EMEA/H/C/000236 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
45 studies that test it; most in 2012 (6)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2002 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 5 |
| 2018 | 3 |
| 2019 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 22 · Other 23
ApoPharma (18) · University Hospital, Lille (5) · Ain Shams University (3) · Lipomed (2) · Neuroscience Trials Australia (1) · Chiesi Canada Corp (1) · Consorzio per Valutazioni Biologiche e Farmacologiche (1) · Imperial College London (1)
Often tested with
Tested in the same studies.
Deferoxamine (5) · Deferasirox (2) · Moxifloxacin (1) · Diarylheptanoids (1) · Acetylcysteine (1) · Vitamin E (1) · Alpha-Tocopherol (1) · Blood Transfusion (1)
Related medicines
As reviewed, each with the page that says it.
- One of Iron chelators source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Deferiprone.
- Jun 2027Early Screening and Treatment of Heart Complication in Sickle Cell DiseasePhase 2 · Inova Health Care Services
Studies
Open first, then newest update. How each study uses Deferiprone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 45
- Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction PatientsRecruitingPhase 2Rohan DharmakumarNCT05604131Written as Deferiprone Tablets
- Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in SchizophreniaRecruitingPhase 2Amit LotanNCT07759895Written as Deferiprone (DFP)
- Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruitingPhase 2Inova Health Care ServicesNCT07023666Written as Deferiprone
- Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedPhase 2/3University Hospital, LilleNCT00943748Written as deferiprone
- Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesCompletedNot applicableUniversity Hospital, LilleNCT02880033Written as deferiprone
- Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) PatientsCompletedPhase 2University Hospital, LilleNCT02164253Written as Deferiprone
- Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseCompletedPhase 2University Hospital, LilleNCT02655315Written as Deferiprone
- Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral SclerosisCompletedPhase 2/3University Hospital, LilleNCT03293069Written as Deferiprone
- Deferiprone to Delay Dementia (The 3D Study)CompletedPhase 2Neuroscience Trials AustraliaNCT03234686Written as Deferiprone 600mg delayed release tablets
- Study of Parkinson's Early Stage With DeferiproneCompletedPhase 2ApoPharmaNCT02728843Written as Deferiprone
- Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young ChildrenCompletedPhase 4Chiesi Canada CorpNCT03591575Written as Deferiprone oral solution
- Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other AnemiasTerminatedPhase 4ApoPharmaNCT02443545Written as Deferiprone
- Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)Status unknownPhase 2Ente Ospedaliero Ospedali GallieraNCT00907283Written as Deferiprone
- Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other AnemiasTerminatedPhase 4ApoPharmaNCT02041299Written as Deferiprone
- Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric PatientsCompletedPhase 3Consorzio per Valutazioni Biologiche e FarmacologicheNCT01825512Written as Deferiprone
- Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated NeurodegenerationCompletedPhase 3ApoPharmaNCT02174848Written as Deferiprone oral solution
- Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast AgentWithdrawnPhase 3CorMedixNCT01391520Written as deferiprone
- A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedPhase 2Imperial College LondonNCT01539837Written as Deferiprone 20mg
- Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)CompletedPhase 3ApoPharmaNCT01741532Written as Deferiprone oral solution
- Combination Deferasirox and Deferiprone for Severe Iron Overload in ThalassemiaCompletedPhase 1/2Children's Hospital of PhiladelphiaNCT01709032Written as Deferasirox and deferiprone
See all 45 studies that test Deferiprone →
Given beside what is tested · 2 — Deferiprone is usual care or a partner of the new treatment
- Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac DiseasesTerminatedPhase 2Carelon ResearchNCT00115349Written as Deferiprone (L1)
- Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia MajorCompletedPhase 4Ospedale MicrocitemicoNCT00800761Written as Deferoxamine and Deferiprone
Codes
What other systems call Deferiprone · ClinicalTrials.gg INT006740
- MeSH (NLM) D000077543DeferiproneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2BTY8KH53LDEFERIPRONEConfirmed FDA, NLM, Wikidata
- RxNorm 11645Confirmed FDA, Wikidata
- Wikidata Q749664deferiproneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73030DeferiproneOne source FDA
- DrugBank DB08826One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077543 | Deferiprone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2BTY8KH53L | DEFERIPRONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 11645 | — | Confirmed FDA, Wikidata |
| Wikidata | Q749664 | deferiprone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73030 | Deferiprone | One source FDA |
| DrugBank | DB08826 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.